Podcasts about Kidney cancer

Dr. Aly-Khan Lalani and Dr. Chris Wallis discuss how new data from the RAMPART trial strengthens the argument for administering  immune-boosting therapies to patients after surgery. This episode also touches on the human side of cancer care, exploring new ways to measure patient side effects and reduce post-treatment regret through improved  counseling. The doctors finish the conversation by highlighting a promising new combination of repurposed drugs that is offering renewed hope to young patients fighting Renal Medullary Carcinoma.This podcast has been made possible through unrestricted financial support by Johnson & Johnson, Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.ca

In this episode, Dr. Rena Malik explores key issues in urologic cancer detection and management with Dr. Scott Eggener. They discuss the importance of regular testicular self-exams, the risks and limitations of full-body screening scans, and evolving innovations in cancer diagnosis and AI in urology. Listeners will gain practical insights on responsible cancer screening, the potential harms of overtesting, and exciting future directions in non-invasive treatment and technology. Become a Member to Receive Exclusive Content: renamalik.supercast.com Schedule an appointment with me: https://www.renamalikmd.com/appointments ▶️Chapters: 00:00 Testicular Cancer Detection and Self-Exams 01:18 Risks of Delaying Cancer Treatment 03:12 Kidney Cancer and Incidental Findings 04:22 Why Full-Body Scans Can Cause Harm 06:11 Is There Screening for Kidney Cancer? 07:25 Future of Cancer Detection and AI in Urology Let's Connect!: WEBSITE: http://www.renamalikmd.com YOUTUBE: https://www.youtube.com/@RenaMalikMD INSTAGRAM: http://www.instagram.com/RenaMalikMD TWITTER: http://twitter.com/RenaMalikMD FACEBOOK: https://www.facebook.com/RenaMalikMD/ LINKEDIN: https://www.linkedin.com/in/renadmalik PINTEREST: https://www.pinterest.com/renamalikmd/ TIKTOK: https://www.tiktok.com/RenaMalikMD ------------------------------------------------------ DISCLAIMER: This podcast is purely educational and does not constitute medical advice. The content of this podcast is my personal opinion, and not that of my employer(s). Use of this information is at your own risk. Rena Malik, M.D. will not assume any liability for any direct or indirect losses or damages that may result from the use of information contained in this podcast including but not limited to economic loss, injury, illness or death. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us Fan MailJoin us as we talk to Annie Anderson to get a patient view on advanced kidney cancer and its treatment.Annie was diagnosed with stage IV Kidney Cancer in 2022 which had spread to liver, bone, brain.She went from climbing and running 18 miles to struggling to function.She describes the choices she made and how immunotherapy with has controlled her cancer and allowed her to continue her normal life.A really powerful thing to hear how Annie has tackled her diagnosis and aimed to take positive steps every day.She describes how continuing the things that give her joy like family, cold-water swimming and climbing have allowed her retain her sense of self along the way.You cannot help but be inspired.Enjoy

Send us Fan MailJoin us as we complete our tour of the adjuvant kidney cancer treatment space.We are joined again by the excellent Dr Will Ince from Cambridge and Dr Naveen Vasudev from Leeds!In our last episode we discussed KEYNOTE 564 and the RAMPART study and where this places immunotherapy in adjuvant kidney cancer.In this episode we discuss the LITESPARK 022 trial and the addition of Belzutifan to Pembrolizumab in adjuvant kidney cancer treatment.We also discuss the potential for KIM-1 to be used as a biomarker to highlight those higher risk patients that may benefit from adjuvant immunotherapy.This is an exciting time for adjuvant treatment in kidney cancer.All this as Will continues to misbehave to amuse himself!!We hope you enjoy! 

Send us Fan MailJoins us as we celebrate 100 episodes in style!!In the first of our 2 part special we tackle the Adjuvant Treatment Landscape in Kidney Cancer.We talk to Dr Will Ince from Addenbrookes Hospital Cambridge and Dr Naveen Vasudev from St James's Hospital Leeds.We discuss the arrival of immunotherapy with the KEYNOTE 564 trial.We discuss the importance of the RAMPART study and backing up the concept of a survival signal from immunotherapy in adjuvant Kidney cancer.We discuss our concept of risk and benefit.Nav steers us through this evolving landscape whilst Will Ince generally misbehaves!!!Enjoy

Behind every kidney cancer diagnosis is a person navigating difficult decisions about treatment and care. Today, we're diving into how to navigate the side effects of kidney cancer treatments and how to tell the difference between side effects and warning signs. This episode is supported by Exelixis.  In this episode we heard from:  Andrew Allers was diagnosed incidentally with clear-cell Renal Cell Carcinoma (RCC) in 2015 after a soccer injury. After a radical nephrectomy and four years of monitoring, Andrew's stage IV diagnosis was made in 2019 with metastases in his rib, hip, lungs and lymph nodes. The bone tumors were radiated, and after two rounds of an immunotherapy combination, a serious auto-immune reaction necessitated a pause in treatment while Andrew's care team figured out a solution. With regular IVIG infusions to manage the adverse reactions, a single-agent immunotherapy was restarted in early 2020 and within a few months a set of scans showed remarkable improvement -- tumors still visible, but "clinically unmeasurable" in the words of his oncologist. Just over a month later, a vision issue took Andrew to the local ER where he was diagnosed with two brain metastases, one of which was in the occipital lobe. The following day an emergency craniotomy was performed, followed by a round of brain radiation. Over the next 18 months, a series of 4 more brain tumors were discovered, radiated and added to the monitoring schedule. Since beginning a TKI in 2022 Andrew has been free of new brain metastases, and the immunotherapy continues to keep the lung and lymph node tumors at bay. After retiring in 2023, Andrew has become active in the Kidney Cancer community, participating in the research grant review process in the CDMRP & KCRP and as a Legislative Advocate for KidneyCAN, an advocacy group that campaigns for federally funded research into Kidney Cancer treatments. Julia Stevens, PharmD, BCOP  is a Clinical Pharmacy Specialist in Ambulatory Oncology at Beth Israel Deaconess Medical Center in Boston, MA. She collaborates with medical oncologists to care for patients with kidney cancer. Her primary clinical responsibilities include educating patients and caregivers, monitoring and supporting those on oral therapies, minimizing the financial toxicity of treatment, and providing drug information and treatment recommendations to her team. Dr. Stevens is also a member of the Kidney Cancer Association Clinical Advisory Board. Rimda Wanchoo, MD is a Professor of Medicine at the Zucker School  of Medicine and full time nephrologist at Northwell Health in NY. She graduated from medical school in India followed by residency at St. Barnabas in New Jersey and fellowship at NY Presbyterian at Weill Cornell.  Her interests are taking care of patients with cancer and kidney diseases, glomerular disease and end stage kidney disease. She has been at Northwell for the last 14 years . She also serves as director of quality for the division and medical director of the largest joint venture dialysis unit in the health system. She has published and spoken on several onconephrology topics internationally. She serves as an associate editor for JON and CKJ. She is one of the founding members of American Society of Onconephrology (ASON).   Additional Resources Kidney Cancer  Kidney Cancer: Treatment and Living Well  Voices for Kidney Health  Kidney Cancer Association (KCA)  KidneyCAN    Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

In this episode of The Checkin, Dwyane Wade and Bob are joined by Dr. Clayton Lau, a urologic surgeon at City of Hope, for an honest conversation about men’s health and why avoiding the doctor can be dangerous. Dwyane opens up about being diagnosed with stage 1 kidney cancer, the fear that came with it, and how finding the right doctor changed everything. Dr. Lau walks through the successful surgery, explaining how robotic-assisted technology allowed for precision and a smooth recovery, even with added complexity during the procedure. Together, they talk about why men often delay care, the importance of routine screenings like colonoscopies and PSA tests, and why taking health seriously is not selfish but necessary to be present for family and life. The episode closes with a look at where medicine is headed and a reminder that we maintain our phones better than our bodies, and it may be time to change that. Music Credit: Khari Mateen. What We Discussed: 00:00 Introduction 02:47 Checkin With Dr Clayton Lau 04:36 The E-bike Story 04:54 Checkin With Dwyane 05:46 MBBS Specialty: Urology 08:37 Dr Clayton: Experience & Journey In Urology 10:31 Robotic Assistant Surgery 17:28 Types Of Cancers & Risks 20:50 In-N-Out Burgers 22:59 Advocating For Self Health 25:59 Does The Doctor See A Doc? 27:43 How To Get Proactive With Your Health 33:28 Unnecessary Questions Before Surgery 35:36 Dealing With The Fear Of Health Complications 38:03 Robots Vs Humans In Healthcare 41:43 Dwyane's CT Scan 48:30 Best Practices To Maintain A Healthy Body 50:00 Debunking Kidney Surgery Myths See omnystudio.com/listener for privacy information.

In this week's Talking Health, Jessica is joined by consultant radiologist, Dr Alex King, to discuss new guidelines fromthe National Institute for Health and Care Excellence, or NICE, which have officially given the green light to thermal ablation to treat kidney cancer on the NHS.

On episode 738 of the 40+ Fitness Podcast, host Coach Allan is joined by urologic oncology expert Dr. Nitin Yerram to shed light on a topic that hits especially close to home—kidney cancer. As Coach Allan himself recovers from a recent radical nephrectomy, he shares his own journey, making this conversation both timely and deeply personal. Together, they dive into why kidney cancer is being diagnosed at younger ages, the often subtle signs and symptoms to watch out for, and the realities of detection—including why blood in the urine is a red flag that can't be ignored. Dr. Yerram unpacks what to expect from a diagnosis, clarifies the risks and treatment options, and provides actionable advice on lifestyle and prevention. This episode isn't just for those facing a diagnosis—it's a must-listen for anyone wanting to be proactive about their health. Time Stamps: 05:39 Early Cancer Diagnosis Trends 07:32 Kidney Cancer: Signs & Discovery 10:11 Discuss Symptoms with Doctor 15:43 Kidney Masses: Fluid vs. Solid 18:11 Renal Cancer Risks Explained 23:23 Imaging Key for Kidney Cancer 25:23 Kidney Masses: Biopsy vs Removal 31:26 Kidney Cancer Treatment Options 35:32 Perils of Misinformation in Diagnosis 38:15 Keys to Health and Wellness 39:56 Kidney Cancer Resource Center https://kidneycancerresourcecenter.org   

Recorded live at EAU26 in London, this special podcast episode features Prof. Brian Rini (US) and Prof. Tom Powles (GB) hosting an interactive UROmigos discussion with experts from the audience.The session explores evolving treatment strategies and key debates in bladder and kidney cancer, highlighting emerging evidence and its potential impact on clinical decision-making.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode, UROONCO RCC chief editor Dr. Carmen Mir talks to Prof. Jose Karam on the results of the LITESPARK-022 study: Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomised phase 3 LITESPARK-022 study.The LITESPARK-022 study will be also presented and discussed at the upcoming EAU26 on Saturday 14th March in the Game Changer Session. Don't miss the chance to hear more on this important study.This interview was recorded at ASCO GU26. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Dr. Aly-Khan Lalani and Dr. Christopher Wallis also discuss the RAMPART trial, LITESPARK-011, and the K-COMPASS model. This final recap episode highlights how evolving adjuvant strategies and combination sequencing are reshaping the kidney cancer landscape. Be sure to listen to Episodes 35 and 36 for the full ASCO GU recap, covering key updates in prostate and bladder cancer!The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Pfizer, Tolmar, AbbVie, Astellas, Eisai, Ipsen, Merck, Bayer, TerSera.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

Listen and subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, www.moneymakingconversations.com/subscribe/ or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

My surgery is now behind me, and things appear to be going well. I have my first follow-up in a few days, so this is everything I know as of the date of recording.

Send a textJoin us as return to our excellent conversation on biomarkers in kidney cancer with the wonderful Professor Laurence Albiges from Paris.

Send a textJoin us for a special Kidney Cancer treat!!!A Must Listen episode!!We discuss the role of biomarkers in advanced kidney cancer with the wonderful Professor Laurence Albiges from the Gustave Roussy Institute of Oncology in Paris.No Kidney Cancer talk is complete without the question -" Where are we with biomarkers?"This is part 1 of a 2 part walkthrough of the biomarker story so far in kidney cancer.Laurence is unequalled in her clear delivery on this subject.As lead for the CARE-1 study Laurence is examining the role of PDL1 as a biomarker in 1st line treatment of mRCC.We also discuss the;- IMDC criteria- Clusters- KIM-1- PDL1- Sarcomatoid featuresRecorded before Christmas this is a gift that keeps on giving.We hope you enjoy!!Check the Transcript for more details.

Listen and Subscribe to Money Making Conversations on iHeartRadio, Apple Podcasts, Spotify, or wherever you listen to podcasts. New Money Making Conversations episodes drop daily. I want to alert you, so you don’t miss out on expert analysis and insider perspectives from my guests who provide tips that can help you uplift the community, improve your financial planning, motivation, or advice on how to be a successful entrepreneur. Keep winning! Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Anthony Tuggle. Senior executive, transformational advisor, and founder/CEO of Tag Us Worldwide. With more than 30 years of leading global operations at AT&T and other Fortune 10 organizations, Tuggle shares lessons in leadership, resilience, corporate success, personal health battles, entrepreneurship, and the importance of emotional intelligence in the AI era. His story blends professional excellence with survival, detailing how he overcame kidney failure, a transplant, dialysis, and even kidney cancer—while simultaneously rising to the executive ranks and later launching his own leadership transformation company.

Send us a textJoin us is as we celebrate Kidney Cancer week with a Masterclass walk through metastatic Renal Cancer with Professor Ricky Frazer from Velindre Cancer Centre.Ricky is a co-host of the hugely successful Immunobuddies podcast and has a vast experience in immunotherapy management.We look at the indications for immunotherapy versus anti-VEGF TKI therapy.Should we just accept anti-VEGF TKI monotherapy in Favourable Risk patients?When should we try IO/IO combination versus IO/TKI combinations in the first line setting?All this whilst Ricky looks to put John in his place!!Enjoy

Update Series: The Role of Nephrectomy in Advanced Kidney Cancer Host: Mark L. Gonzalgo, MD, PhD, MBA Guest: Sarah P. Psutka, M.D., M.S., F.A.C.S. Now in its 45th installment, the AUA Update Series is renowned for delivering high-quality lessons to practicing urologists, fellows and residents. All content is developed by internationally recognized experts in urology, making the AUA Update Series the most professional and sought-after self-study program available. Improve your practice and patient care by staying abreast of the latest treatments and surgical techniques in urology. For more information or to subscribe to the AUA Update Series, please visit CME.auanet.org

Joshua Silva did not take lower back pains and gastrointestinal issues seriously until they worsened, forcing him to visit an emergency room.  A CT scan revealed inflammation of his appendix, necessitating an appendectomy.  A urologist said the scan also showed a problem in his left kidney, later diagnosed as clear cell renal cell carcinoma, a type of kidney cancer.  Joshua underwent a partial nephrectomy knowing before the procedure he may lose the kidney.  When he regained consciousness after the procedure, a nurse told him the kidney was spared.  Post-treatment medication and weekly visits to a therapist enabled him to get very close to his pre-diagnosis health.  Among other positive developments, Joshua Silva has resumed one of his major passions, that of playing golf.   Lots of people experience gastrointestinal problems and lower back pain, so when this happened to Joshua Silva of Houston, Texas, a man in his early thirties, he thought with time the problems would go away.  But that didn't happen.  One night the pain became so bad that he couldn't sleep, and he decided to go to the emergency room.   He underwent a CT scan which indicated an inflamed appendix but also showed problems with his left kidney.  What Joshua knew was that he would have to undergo an appendectomy.  What he didn't know with certainty was just what was wrong with his kidney.  Some doctors said the problem might by a cyst or might be cancer.  Joshua prepared himself for the worst and began to think what life would be like if he was diagnosed with cancer and had to go forth with one kidney.   His appendix was removed, but he had to wait an excruciating four weeks to see a urologist, who said he didn't need a biopsy to determine Joshua had clear cell renal cell carcinoma, a form of kidney cancer.    Because the diagnosis came shortly before the holidays, the urologist accelerated the timetable for a partial nephrectomy, seeking to form a care team before its members left for vacation.  The urologist said the margins around the tumor would determine whether he could spare the left kidney or have to remove it.    Even though he was under anesthesia for the procedure, as soon as he regained consciousness, he wanted to know the status of his kidney.  A nurse told him the urologist was able to remove the cancer without removing the kidney.   Just when it seemed like Joshua was on his way toward survivorship, he received some bad news.  The incision point for the partial nephrectomy was very close to the incision point for the appendectomy.  The appendectomy incision had not fully healed, resulting in an infection.  His abdomen area began to swell and turn red.  Antibiotics prescribed after the partial nephrectomy did nothing to address the pain. It was a very difficult three weeks, as Joshua dealt with the pain and sudden uncertainty as to whether he could keep his left kidney.   He was put on a different medication regimen and after three more weeks, the pain and swelling went away.  A subsequent scan showed that he was cancer free.   Joshua Silva says his health is now about 98 percent of what it was prior to his back pains and GI issues, and back out on the links with a single-digit handicap.   Additional Resources:   Support Group:   The Kidney Cancer Association  https://www.kidneycancer.org      

This podcast episode is sponsored by AVEO Oncology.  The product information in this podcast is intended only for US residents.  This episode features a real patient and their care partner, highlighting their experiences with a treatment option for advanced kidney cancer.  Please note that the patient's experience is their own and individual results may vary.  This podcast is not intended as medical advice.  Only a doctor can decide what medications may be appropriate for you.  The patient and the caregiver were paid for their time and expenses.        I'm honored to welcome Scott and Katie to the program. Scott's journey began in July 2021, when he started experiencing symptoms that ultimately led to a diagnosis of renal cell carcinoma, resulting in the removal of his right kidney. At first, no additional treatments were needed. But in January 2023, after a biopsy of a lesion in his lung, Scott learned that his cancer had returned as stage IV metastatic renal cell carcinoma.   Today, we're joined by Scott and his wife Katie, who share their journey with renal cell carcinoma – the challenges they've faced, the lessons they've learned, and the support they've discovered along the way. Their story is not only about facing a difficult diagnosis, but also about the strength of partnership, perseverance, and hope.     Through their experience, Scott and Katie remind us that no one has to face kidney cancer alone—there's a community of understanding and shared strength every step of the way. Whether you're a patient, a care partner, or simply someone seeking hope and information, we believe you'll find inspiration and connection in Scott and Katie's story.      Important Safety Information: Before taking FOTIVDA, tell your healthcare provider about all your medical conditions including, if you have high blood pressure, a history of heart failure, a history of blood clots in your veins or arteries (including stroke, heart attack, or change in vision), bleeding problems, thyroid problems, , liver problems, an unhealed wound, if you plan to have surgery or have had recent surgery, or are allergic to FD&C No. 5 (tartrazine) or aspirin. Tell your healthcare provider if you are pregnant or planning to be. FOTIVDA can harm your unborn baby. If you are able to become pregnant: -Your healthcare provider should do a pregnancy test before you start treatment. -Use effective birth control (contraception) during treatment and for 1 month after your last dose. -Talk to your healthcare provider about birth control methods that may be right for you. -Tell your healthcare provider right away if you become pregnant or think you might be pregnant. -Do not breastfeed during treatment and for 1 month after your last dose of FOTIVDA. Tell your healthcare provider about all the medicine you take and any new medicine. Taking FOTIVDA with certain other medicines may affect how FOTIVDA works. FOTIVDA may cause serious side effects, including: High blood pressure (hypertension). High blood pressure may be severe, including a sudden, severe increase in your blood pressure (hypertensive crisis) that can lead to death. You should check your blood pressure regularly and tell your healthcare provider if you have increased blood pressure or experience confusion, headaches, dizziness, chest pain, or shortness of breath. Heart failure. Heart failure may be serious and sometimes lead to death. Your healthcare provider should check for symptoms of heart failure regularly, such as shortness of breath or swelling of your ankles. Heart attack and blood clots in your veins or arteries. Blood clots may be serious and sometimes lead to death. Tell your healthcare provider or get emergency medical help right away if you have, new chest pain or pressure, numbness or weakness on one side of your body, pain in your arms, back, neck or jaw, trouble talking, shortness of breath, sudden severe headache, vision changes, swelling in the arms or legs Bleeding problems. Bleeding may be serious and sometimes lead to death. Report or get medical help right away if you have, unusual bleeding from the gums, red or black stools (looks like tar), menstrual bleeding or vaginal bleeding that is heavier than normal, bruises that happen without a known cause or get larger, headaches, feeling dizzy or weak, bleeding that is severe or you cannot control, coughing up blood or blood clots, pink or brown urine, vomiting blood or your vomit looks like “coffee grounds,” unexpected pain, swelling, or joint pain Protein in your urine. Your healthcare provider should check your urine for protein before and during treatment. Tear (perforation) in your stomach or intestines or an abnormal connection between two or more body parts (fistula). Get medical help right away if you experience tenderness or pain in your stomach-area (abdomen) that is severe and does not go away. Thyroid gland problems. Your healthcare provider should do blood tests to check your thyroid gland function before and during your treatment and may prescribe medicine if you develop thyroid gland problems. Risk of wound-healing problems. Wounds may not heal properly during treatment. Tell your healthcare provider if you plan to have surgery before starting or during treatment, including dental surgery. You should stop taking FOTIVDA at least 24 days before planned surgery. Your healthcare provider should tell you when you may start taking FOTIVDA again after surgery. Reversible Posterior Leukoencephalopathy Syndrome (RPLS). RPLS is a condition that can happen. You're your healthcare provider right away if you have headaches, seizures, confusion, blindness or changes in vision, or difficulty thinking. Allergic reactions to tartrazine (FD&C Yellow No. 5). FOTIVDA contains a dye called FD&C Yellow No. 5 (tartrazine) that may cause allergic-type reactions, including bronchial asthma, in certain people. This occurs most often in people who also are allergic to aspirin. Common side effects include tiredness, diarrhea, decreased appetite, nausea, hoarseness, low levels of thyroid hormones, cough, mouth sores, decreased blood levels of salt (sodium) and phosphate, increased levels of lipase in the blood. Other side effects include vomiting and weakness or lack of energy. FOTIVDA may cause fertility problems in males and females, which may affect your ability to have a child. Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with FOTIVDA if you have certain side effects. These are not all the possible side effects of FOTIVDA. To report SUSPECTED ADVERSE REACTIONS, contact AVEO Pharmaceuticals, Inc. at 1-833-FOTIVDA (1-833-368-4832) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Please see the Patient Information in the full Prescribing Information at fotivda.com Thank you again for tuning into ‘Wait, How Do You Spell That?' and for listening to Scott and Katie's story.  No matter where you are on this journey, there's a caring community here to support you and you are not alone.        

The UROONCO RCC editorial board chief editor Dr. Carmen Mir, and associate editors Dr. Teele Kuusk, Dr. Riccardo Bertolo and Assoc. Prof. Carlotta Palumbo share and discuss highlights of the important kidney cancer developments for 2025. They summarise the developments in diagnostics and early detection, systemic therapy and perioperative treatment. They also talk about surgical and robotics innovations, tumour biology, and anticipated advances expected in 2026.To learn more on the highlights discussed in this podcast, check out this report on kidney cancer highlights in 2025.  For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode of Navigating Cancer TOGETHER, host Talaya Dendy welcomes back award-winning journalist, poet, and two-time cancer survivor Annamaria Scaccia. Annamaria shares her powerful story of surviving both kidney and thyroid cancer by age 40 and how she is transforming her life through bodybuilding and advocacy. They discuss the psychological power of strength training, the challenges of managing rare cancer types, how cancer impacts relationships, and the importance of self-awareness in the healing process. Tune in to discover how physical discipline, raw truth, and giving yourself grace can help you reclaim your power and navigate the complex emotional landscape of long-term survivorship.✨Episode Highlights:00:02:32 Annamaria's Origin Story00:05:39 Transitioning from Kickboxing to Bodybuilding after a Kidney Cancer Diagnosis00:09:18 Bodybuilding for Healing and Trauma Recovery00:17:45 Self-Awareness and the Truth of the Iron00:20:50 Navigating a Second Cancer Diagnosis00:27:41 Addressing Multiple Primary Cancers Transcript: https://bit.ly/podscript178Connect & Engage with Annamaria:Links: https://linktr.ee/gotchascaccia?utm_source=linktree_profile_share<sid=e18723c7-b1a1-4be2-9794-507317879f6cInstagram: https://www.instagram.com/gotchascaccia/LinkedIn: https://www.linkedin.com/in/annamariascaccia/Podcast: https://www.kidneycancer.org/podcast/National Cancer Survivor Month Episode: https://youtu.be/JlET8Ljujiw?si=f1_b4aAJ_rkTopk2Join the Community: Looking for a safe space to share your raw truth? Join the waitlist for the Navigating Cancer TOGETHER Cancer Community Forum. Connect with others in a private, supportive environment completely free from the noise and distractions of social media. Be the first to know when we open: https://www.ontheotherside.life/forum-waitlistSponsor: This episode is brought to you by On the Other Side. Thank you for your support! It helps to bring these critical conversations to life.Hosted, Produced, Written, and Edited by: Talaya DendyDisclaimer: The information on this podcast is for general informational purposes only and SHOULD NOT be used as a substitute for sound professional medical advice, evaluation, or care from your physician or other qualified health care provider.Hosted on Ausha. See ausha.co/privacy-policy for more information.

UROONCO RCC chief editor Dr. Carmen Mir (US) talks to Dr. Lorenzo Bianchi (IT) on his lecture "RCC with venous thrombosis: optimal imaging for surgical planning and imaging-guided surgery".This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Comments? Questions? Send us a message!Steve Marquez is husband to Monica, and father of Cody, Jared, and Andrew. Steve is a pastor, a teacher, a former church planter, a musician, a former journalist, photographer, and founder of a non-profit ministry called Stage 4 Ministries. Monica, Steve's wife, is her husband's co-laborer in life and also in ministry, She is a super effective and fruitful minister in her own right.  In 2014, the Marquez family received astonishing and shocking news. Steve was diagnosed with stage 3 Renal Cell Carcinoma (RCC), which is kidney cancer. Later, it was discovered that he had stage 4, metastatic RCC. Eventually, he and Monica started Stage 4 Ministries. That story is told in podcast 158 of Strength for Today's Pastor.So, what's new with Stage 4 Ministries? Steve and Monica are excited about Solace, a new way of serving not only potential end of life cancer patients, but also the ones who provide care (caregivers). Solace is a ministry tool and template for any church seeking to provide such care, not only to church congregants, but also to the surrounding community.Listen in for more, and find out how you can gain a deep dive understanding of how the Lord might use Solace and Stage 4 Ministries in your ministries.Spoiler alert: the exciting, God-glorifying story of Steve's healing is also contained in this episode!ResourcesBook: Grace for the BattleBlog: https://stmarq.substack.com/Website: https://www.stage4ministries.com/For Poimen Ministries, its staff, ministries, and focus, go to poimenministries.com. To contact Poimen Ministries, email us at strongerpastors@gmail.com. May the Lord revive His work in the midst of these years!

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a series of significant developments that underscore the rapid evolution within these industries.Starting with one of the major players, Merck, which has been strategically adjusting its focus in light of Keytruda's looming loss of exclusivity. The company has demonstrated remarkable progress with Welireg in kidney cancer trials, successfully pairing it with Keytruda. This combination therapy is a beacon of hope for Merck as it faces the challenges of patent expiration, highlighting the growing trend toward leveraging combination treatments to enhance efficacy in cancer therapies. This approach not only pushes the boundaries of cancer treatment but also paves the way for future therapeutic innovations. In contrast, Merck and Eisai have decided to cease their pursuit of a Keytruda-Lenvima pairing for a specific liver cancer subtype after failing to achieve overall survival benefits, despite earlier progress-free survival gains. Such developments highlight the inherent uncertainties in oncology drug development, where initial promising results may not always lead to long-term survival advantages.Meanwhile, Eli Lilly is making headlines with its substantial $1.2 billion investment to upgrade its Puerto Rico manufacturing facility. This move is aligned with their strategy to amplify production capabilities for oral drugs, particularly focusing on their promising GLP-1 pill, Orforglipron. The investment signifies a robust commitment to addressing diabetes and potentially other metabolic disorders through an expanded and more efficient production pipeline. Additionally, Eli Lilly's collaboration with NVIDIA aims at constructing an unprecedented supercomputer tailored for pharmaceutical research. This initiative leverages advanced computational power to accelerate drug discovery processes and enhance data analysis capabilities—a testament to how AI and machine learning are streamlining research workflows for developing more effective therapeutics.On the regulatory stage, Akebia Therapeutics has opted to cancel a trial for its anemia drug Vafseo after discussions with the FDA. This decision sheds light on the intricate challenges companies encounter while navigating regulatory landscapes and optimizing clinical trial strategies to ensure market success.In legal news, Kenvue is preparing for a lawsuit filed by Texas Attorney General Ken Paxton regarding alleged deceptive marketing practices about Tylenol's safety during pregnancy and its purported link to autism risk. This case emphasizes the necessity for pharmaceutical companies to uphold rigorous scientific evidence supporting their marketing claims while navigating potential legal challenges.Strategically, WuXi AppTec's decision to divest its China-based clinical research units marks a broader industry trend of streamlining operations to concentrate on core competencies. By focusing resources on its Contract Research Development and Manufacturing Organization (CRDMO) platform, WuXi aims to leverage growth opportunities in this burgeoning sector.In a notable technological partnership, Johnson & Johnson's medical technology division and Verily have entered agreements with NVIDIA, highlighting the increasing intersection of artificial intelligence with life sciences. These collaborations are poised to advance AI applications within healthcare, potentially transforming areas such as data analysis, diagnostics, and personalized medicine.The industry is also feeling the impact of governmental actions, as evidenced by a federal government shutdown starting October 1st that has led to indefinite blocks on federal worker firings. Such political developments can significantly affect healthcare funding and policymaking processes.These stories collectively paint a piSupport the show

Wrapping up our live ESMO 2025 coverage from Berlin, Germany, Dr. Aly-Khan Lalani and Dr. Christopher Wallis review pivotal kidney cancer data, including RAMPART's results, emerging first-line combinations from KEYMAKER-U03 and more, offering a forward-looking view of where RCC research is heading next.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

Today's guest is Phil Richards MBE, living with advanced, incurable kidney cancer since 2018. He has used this experience to elevate his understanding of what truly matters, sharing his life lessons with the world. He was also awarded the prestigious MBE (Member of the British Empire) at Windsor Castle by Princess Anne in 2021.We talk about living with Stage IV cancer, sharing with family and how these relationships change and grow, Phil's mindset and resilience life lessons and his PROOF Framework, quantity vs. quality of life, a powerful question from an 11 year old, and so much more.Optimism is one of the pieces of the PROOF framework, and Phil truly exudes that. You are going to be so inspired by this conversation. I know I am!Resources:Phil's Website: http://philrichardsmbe.com/Phil's LinkedIn: https://www.linkedin.com/in/phil-richards-mbe-44ba352a6/Phil's Email: phil@philrichardsmbe.comFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Silke, Tom and Brian discuss the prostate and RCC highlights from ESMO 2025

Show notes and links: www.chrisbeatcancer.com/how-murray-cluley-healed-stage-iv-kidney-cancer-naturally

UROONCO RCC associate editor Dr. Riccardo Bertolo (IT) talks to Prof. Jean-Christophe Bernhard (FR) about the lectures he presented during the ERUS25 Meeting. Prof. Bernhard discusses surgical training for the next generation of urologists, sharing practical advice and guidance to help young surgeons grow in their careers, as discussed in his Young ERUS lecture. He also shares details of his presentation on "Complex surgery of robotic nephrectomy in level 3 caval thrombus", and provides insights into treatment strategies, highlights the most critical preoperative considerations, and shares practical tips and tricks. He concludes with his opinion on whether robotic surgery represents the future for managing such challenging cases.This interview was recorded at ERUS25 in London, United Kingdom. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

If you're curious as to if you have any stored emotions or trauma that might be causing your illness, preventing you from achieving your or even just showing up as the best, authentic version of yourself, I invite you to take my free Stored Emotions and Trauma Quiz How often do you think about your kidneys?In this episode, I sit down with Dr. Robin Rose, a longtime voyager and pioneer in conscious and holistic healing whose path went from nursing to nurse practitioner to medical school. Her passion for kidney health was sparked by her own experience with kidney cancer and kidney disease, and the decade-long recovery that led her to a new paradigm she calls phenology, the art and clinical science of kidney success.We talk about exactly what to look for in labs (including how to think about GFR), the emotional and spiritual energetics behind kidney dysfunction, and the top lifestyle moves to make when kidney function isn't where it should be. We also get into why kidneys are so often overlooked in medicine and how Dr. Rose rebuilt her health after a nephrectomy. You'll Learn:Labs to consider for assessing kidney healthWhat a healthy GFR level isEnergetics, emotional, and spiritual aspects underlying kidney dysfunction and diseaseTop 10 lifestyle changes for poor kidney functionThe hidden early signs of kidney decline most doctors missHow conventional and even functional medicine often overlook kidney healthKey lifestyle shifts that can improve kidney performance and energy levelsThe quiet damage high animal protein diets can cause in compromised kidneysWhat it feels like to rebuild health after losing a kidneyHow spiritual practices and mindset can influence physical healingThe overlooked role of kidney tubules and how to test their functionPractical ways to reduce kidney-toxic exposures in daily lifeTimestamps: [00:00] Introduction [05:44] Robin shares her journey through illness, surgery, and kidney cancer diagnosis [14:59] Discovering functional and regenerative approaches to improve GFR [24:53] Emotional, spiritual, and energetic aspects of kidney health [34:27] Why kidneys are often overlooked in conventional and functional medicine [42:58] Understanding kidney tubules and overlooked testing options [53:22] Diet changes that protect kidney function and common mistakes to avoid [1:02:47] Reducing toxins and environmental exposures that harm kidneys [1:12:55] Mindset, self-love, and adapting to support long-term healing [1:21:40] Key lifestyle factors for kidney regeneration and successResources Mentioned:Renology Peptides by Robin Rose | BookLearn more from Robin by checking out her websiteFind More From Dr. Stephanie Davis:Dr. Stephanie Davis | WebsiteQuantum Rx | InstagramQuantum Rx | Skool

Nutritionist Leyla Muedin reveals the alarming increase in obesity-associated cancers in the United States over the past two decades. Highlighting findings from a recent study presented at the Endocrine Society's annual meeting, Leyla underscores the significant rise in cancer deaths linked to obesity, particularly among women, older adults, Native Americans, and Black Americans. She also explores the complex causes of obesity, including genetics, lifestyle, and environmental factors, and offers insights into effective weight management strategies. Additionally, Leyla examines the high rates of heart disease in various U.S. states, emphasizing the importance of lifestyle modifications and public health initiatives to combat cardiovascular diseases.

In this episode of Kidney Cancer Unfiltered, we spotlight the often-overlooked experiences of Native American communities in the context of kidney cancer. Experts Dr. Monica Yellowhair of the Arizona Cancer Center and Dr. Ken Batai of Roswell Park Comprehensive Cancer Center share research findings on health disparities, barriers to care, and the need for culturally respectful treatment in tribal communities.Nancy Washburn, also of Roswell Park Comprehensive Cancer Center, brings a vital voice to the conversation — offering a front-line view of what it means to navigate patients through a system full of red tape and limited access. With host Annamaria Scaccia, the conversation emphasizes the crucial role of patient navigators and community health workers in bridging healthcare gaps and ensuring Native patients don't fall through the cracks and calls on providers, researchers, and systems to do better — for ALL patients. Visit kidneycancer.org for more support and resources. Hosted on Acast. See acast.com/privacy for more information.

Today's episode we will cover 2025 updates for metastatic renal cell carcinoma. We will discuss risk categories, treatment options, and variant histologies. We are so excited to have Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos sharing their expertise on today's episode as well!

Today's episode we will cover 2025 updates for localized renal cell carcinoma (RCC) with Dr. Tom Powles and Dr. Brian Rini from the urologic oncology podcast Uromigos! We will discuss risk factors, the presentation, staging, and treatment options. 

Nicole Scott and her husband, Keith, worked at the same Ohio hospital.  When Keith noticed abdominal pain in his left side, he thought it was muscle-related because of the physical nature of his job.  The pain radiated to his groin, then what had been random occurrences of the pain became more frequent.   Nicole urged Keith to seek urgent care.  An emergency room doctor called for a CT scan, thinking Keith had at worst, a hernia.  However, the CT scan revealed a mass on Keith's kidney.  An MRI and partial nephrectomy resulted in a diagnosis of papillary renal cell carcinoma, a form of kidney.   Nicole and Keith were shocked by this diagnosis, but after she got over the shock, Nicole assumed the role of Keith's caregiver.   She said without question, the toughest part of her caregiver experience was the emotional piece.  At first, there was a tremendous amount of fear and depression, as she thought Keith might not survive, but all the while she told herself she was caring for the love of her life, had to put up a positive front and be a source of encouragement for her husband.   Nicole said there was some at-home care involved, but much of her duties consisted of making sure that Keith made it to all of his doctor visits, most notably the successful surgical procedure and post-treatment care.   Caregiving can be a round-the-clock challenge, and Nicole said she came close to suffering from caregiver burnout, but she always did what needed to be done, at all times realizing hers was a high-stakes task.   By way of advice, Nicole Scott says to anyone suddenly finding themselves in the role of caregiver to take a deep breath and never lose hope.  She says a caregiver needs to take of themselves.  She says it is “not selfish” to ask a friend to pitch in or to make time for some ‘me time,' as that will make a caregiver a better caregiver.   Additional Resources:   The Kidney Cancer Association: https://www.kidneycancer.org      

Food manufacturers cave to RFK Jr. agenda to eliminate artificial dyes; Diet, exercise ameliorate tinnitus symptoms in overweight seniors; Long work hours may foster deleterious brain changes; Blood in urine—why is it such a big deal? Suggestions for a dog with panic attacks ahead of weather fronts; Diets high in fruits and vegetables counter disordered sleep.

A Masterclass in advanced kidney cancer today with the great Danny Heng (University of Calgary, Canada), and our own Lewis Au (Peter MacCallum Cancer Centre, Melbourne). Both popped into the GU Cast studio while Danny was in Australia doing some lectures and visiitng us at Peter Mac.We challenged Danny and Lewis to simplify three hot topics in kidney cancer, ideal if (like us) you find it difficult to keep up with this fast-moving area. The three areas are:1. What sort of patient is this? Risk stratification made easy (by Danny, Master of the universe of Risk Stratification in kidney cancer)2. Novel scans and biomarkers in kidney cancer - a bluffers guide 3. Neoadjuvant and adjuvant therapies in kidney cancer - what the urologist needs to know Even better on our YouTube channel

Recorded live in Chicago, your hosts explore the latest in kidney cancer, discussing new five-year follow-up data from KEYNOTE-564, the long-term results of CheckMate 214, insights from the ongoing PDIGREE trial, and much more.The View on GU with Lalani & Wallis integrates key clinical data from major conferences and high impact publications, sharing meaningful take home messages for practising clinicians in the field of genitourinary (GU) cancers. Learn more about The View on GU: theviewongu.caThis podcast has been made possible through unrestricted financial support by Novartis, Bayer, Astellas, Tolmar, Ipsen, J&J, Merck, Pfizer, Eisai and AbbVie.

The Sounds of Nouns & Ozempic Linked to Kidney CancerSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

While rubbing her 3 year old daughter Chelsea's belly, Alison Hicks felt a lump which was shortly diagnosed as a Stage 4 Wilms Tumor. Chelsea fought this Pediatric  Kidney Cancer for nearly 2 years before passing away after a treatment protocol which was very difficult from the beginning to its end. As a result of Chelsea's battle and passing, Alison started the Chelsea Hicks Foundation which focuses on keeping a smile on Pediatric Cancer patients as they go through their impatient hospital treatments. 

Hereditary Kidney Cancer Syndromes CME Available: https://auau.auanet.org/node/41772 ACKNOWLEDGEMENTS: Support provided by an independent educational grant from:  Merck & Co., Inc.  LEARNING OBJECTIVES: At the conclusion of this activity, participants should be able to: 1. Select patients who should undergo genetic testing to identify hereditary kidney cancer syndromes based on appropriate criteria, including family history and clinical presentation. 2. Implement strategies to address ethical concerns related to genetic testing, such as patient consent, confidentiality, and the potential impact on family members. 3. Discuss VHL syndrome, including its genetic basis, inheritance pattern, and associated tumors. 4. Properly diagnose and manage VHL syndrome in clinical practice based on knowledge of novel therapeutic strategies. 5. Utilize a multidisciplinary approach consisting of urologists, oncologists, geneticists and nephrologists when managing hereditary kidney cancer syndromes.

Watch the show on YouTube: https://www.youtube.com/@DrTazMD/podcastsIn this episode, Cameron Mathison sits down with Dr. Taz to share his incredible and inspiring health journey. From his early challenges with a degenerative bone disease to a shocking kidney cancer diagnosis, Cameron's story underscores the importance of being an advocate for one's own health. He reveals how, for years, he was misled by traditional doctors who simply prescribed medications that only made things worse, until he found a path to healing through functional medicine. Cameron discusses his approach to integrating science and spirit, the pivotal role of a functional health coach in his recovery, and his newfound passion for helping others through his venture, Health360. Join us for a compelling story of resilience, the power of functional medicine, and the importance of holistic health practices.Note: This conversation was filmed before Cameron and his family lost their house in the LA fires. Healing is a constant journey and we are sending Cameron and his family lots of love. About Cameron MathisonEmmy nominated actor and Emmy winning TV host Cameron Mathison made his long-awaited return to daytime on ABC's General Hospital, after a decade as fan favorite Ryan Lavery on ABC's All My Children.  He was also the co-host of Hallmark Channel's “Home and Family” alongside Debbie Matenopoulos for three seasons. Mathison is also the creator of allhealth360, a health and wellness destination dedicated to a healthier lifestyle inside and out. He previously served as feature correspondent for “Good Morning America,” “Entertainment Tonight” and “Extra,” and co-hosted the “35th Annual Daytime Emmy Awards.” He recently signed a multi-picture deal with Great American Media and is a host for a new GSN show that is set to premiere in 2024.Thank you to our sponsorTimeline: timeline.com/DRTAZ01:54 A Personal Story from Dr. Taz03:15 Advocating for Men's Health05:50 Cameron's Early Life Health Struggles14:51 Discovering Kidney Cancer17:05 The Healing Journey Begins20:19 The Role of Functional Health Coaching27:57 Cameron's Gut Health Protocol35:42 Cameron's Personal Experience with Healing His Gut43:17 Meditation and Mental Well-being56:10 Encouragement for Men's HealthStay ConnectedSubscribe to the audio podcast: https://holplus.transistor.fm/subscribeSubscribe to the video podcast: https://www.youtube.com/@DrTazMD/podcastsFollow Dr. Taz on Instagram: https://www.instagram.com/drtazmd/Join the conversation on X: https://x.com/@drtazmdTikTok: https://www.tiktok.com/@drtazmdFacebook: https://www.facebook.com/drtazmd/Connect with Cameron Matthison:https://www.instagram.com/cameronmathison/Host & Production TeamHost: Dr. Taz; Produced by Rainbow Creative (Executive Producer: Matthew Jones; Lead Producer: Lauren Feighan; Editors: Jeremiah Schultz and Patrick Edwards)Don't forget to like, subscribe, and hit the notification bell to stay updated on future episodes of hol+

For patients with early-stage cancer, minimally invasive image-guided therapies like cryoablation can be both life-altering and life-saving. Patient Clinton Lanier, a kidney cancer survivor who underwent multiple cryoablations, sits down with host Dr. Eric Keller to share his story and raise patient-provider awareness of the positive impacts IR brings. --- This podcast was developed in collaboration with: Interventional Initiative https://theii.org/ --- SYNPOSIS Clinton shares his personal story of being diagnosed with a kidney tumor during a sailing trip and discovering cryoablation as a treatment option through his own research and advocacy. He discusses the effectiveness and ease of the procedure, the positive impact it has had on his quality of life, and the importance of raising awareness about cryoablation among patients and healthcare providers. --- TIMESTAMPS 00:00 - Introduction 03:56 - First Cryoablation Experience 05:20 - Patient Experience 09:12 - Cryoablation Awareness 14:44 - Conclusion --- RESOURCES The Interventional Initiative: https://theii.org